Our Neurocognitive specialists provide comprehensive diagnostic and treatment care plans for those experiencing memory loss
On January 6th, 2023, the FDA granted accelerated approval for Leqembi (Lecanemab) which is the second FDA-approved therapy for Alzheimer’s Disease.
Leqembi (Lecanemab) specifically targets protofibrils which cluster together and forms the protein plaque beta-amyloid 42.
Memory Treatment Centers is now actively infusing Leqembi.
Donanemab is a biologic infusion that is currently in trial to treat early symptoms of Alzheimer’s disease. Manufactured by Eli Lilly, Donanemab was designed by the FDA as a breakthrough treatment and is expecting approval from the FDA during the summer of 2023.